Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium and Motor Evoked Potential in Brain Tumor Surgery
NCT04768400Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rocuronium in brain tumor, sponsored by Gangnam Severance Hospital. Primary endpoint: Amplitude of the motor evoked potential at induction at 0 hours. Started Mar 2021; status: completed.
02
Drugs
rocuronium
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT04768400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768400.